EP0359282B1 - Anticorps monoclonaux spécifiques du récepteur du facteur de la croissance de l'épiderme humain et compositions thérapeutiques les contenant - Google Patents

Anticorps monoclonaux spécifiques du récepteur du facteur de la croissance de l'épiderme humain et compositions thérapeutiques les contenant Download PDF

Info

Publication number
EP0359282B1
EP0359282B1 EP89117125A EP89117125A EP0359282B1 EP 0359282 B1 EP0359282 B1 EP 0359282B1 EP 89117125 A EP89117125 A EP 89117125A EP 89117125 A EP89117125 A EP 89117125A EP 0359282 B1 EP0359282 B1 EP 0359282B1
Authority
EP
European Patent Office
Prior art keywords
cells
antibody
human
egf
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP89117125A
Other languages
German (de)
English (en)
Other versions
EP0359282A2 (fr
EP0359282A3 (en
Inventor
Joseph Schlessinger
David Givol
Richard Kris
Françoise Bellot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Rorer International Holdings Inc
Original Assignee
Rorer International Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26936756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0359282(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP94117268A priority Critical patent/EP0667165B1/fr
Application filed by Rorer International Overseas Inc filed Critical Rorer International Overseas Inc
Publication of EP0359282A2 publication Critical patent/EP0359282A2/fr
Publication of EP0359282A3 publication Critical patent/EP0359282A3/en
Application granted granted Critical
Publication of EP0359282B1 publication Critical patent/EP0359282B1/fr
Priority to LU91116C priority patent/LU91116I2/fr
Priority to LU91117C priority patent/LU91117I2/en
Priority to NL300167C priority patent/NL300167I1/nl
Priority to NL300166C priority patent/NL300166I1/nl
Priority to NL300350C priority patent/NL300350I1/nl
Priority to NL300351C priority patent/NL300351I1/nl
Priority to LU91449C priority patent/LU91449I2/fr
Priority to LU91448C priority patent/LU91448I2/fr
Priority to NL300353C priority patent/NL300353I1/nl
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to new hybrid cell lines and in particular to hybrid cell lines for production of monoclonal antibodies specific to a human receptor for epidermal growth factor (EGF) which can inhibit the growth of human tumor cells that express human EGF receptors, to the antibodies so produced, to therapeutic compositions containing the antibodies, and to therapeutic compositions containing the antibodies in combination with anti-neoplastic agents.
  • EGF epidermal growth factor
  • Control of cell growth is regulated by the interaction of soluble growth factors and cell membrane receptors.
  • the first step in the mitogenic stimulation of epidermal cells is the specific binding of epidermal growth factor (EGF) to a membrane glycoprotein known as the epidermal growth factor receptor (EGF receptor).
  • EGF epidermal growth factor
  • the EGF receptor is composed of 1,186 amino acids which are divided into an extracellular portion of 621 residues and a cytoplasmic portion of 542 residues connected by a single hydrophobic transmembrane segment of 23 residues.
  • the tumorigenicity of a series of human vulval epidermoid carcinoma (A431) clonal variants implanted into athymic mice having different levels of EGF receptors was found to correlate directly with the level of expression of the EGF receptor (Santon, et al ., Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice, Cancer Res. , Vol. 46, 4701-4700 (1986)).
  • overexpression of EGF receptors play a role in the origin of tumorigenesis of cancer cells.
  • EGF receptor density may be mediated by the interaction of the receptor with its ligands - namely, EGF or transforming growth factor (TGF).
  • EGF transforming growth factor
  • TGF transforming growth factor
  • KB human oral epidermoid carcinoma
  • 184A1N4 and 184A1N4-T - collectively "184" cells are commonly used in studies relating to the EGF-receptor.
  • KB and 184 cells are substantially different from A431 cells, especially in terms of their growth response to epidermal growth factor. KB and 184 cells are growth stimulated by high concentrations of epidermal growth factor whereas A431 cells are growth inhibited by high concentrations of epidermal growth factor.
  • KB and 184 cells provide a more representative pattern of responding to EGF than A431 cells, and, in fact, are used as a model for human tumor cells expressing EGF receptors. (Willington, et al . J. Cell Biol. , Vol. 94, 207-212 (1982)).
  • the primary goal in treating tumors is to kill all the cells of the tumor.
  • a therapeutic agent that kills the cell is defined as cytotoxic.
  • a therapeutic agent that merely prevents the cells from replicating, rather than killing the cells, is defined as cytostatic.
  • Anti-neoplastic or chemotherapeutic agents administered by themselves are effective cytotoxic agents.
  • anti-neoplastic agents such as doxorubicin (adriamycin) and cisplatin, for example, are well known in the art. Use of those reagents by themselves, however, are only effective at levels which are toxic or subtoxic to the patient.
  • Cisplatin is intravenously administered as a 100 mg/m2 dose once every four weeks and adriamycin is intravenously administered as a 60-75 mg/m2 dose once every 21 days.
  • the present invention relates to monoclonal antibodies which inhibit the growth of human tumor cells by binding to the extra-cellular domain of the human EGF receptors of said tumor cells in an antigen-antibody complex, with the tumor cells characterized by their expression of human EGF receptors and by mitogenic stimulation by human EGF, and further, said antibody having the capability of inhibiting the growth of human oral epidermoid carcinoma (KB) cells or human mammary epithelial (184) cells by binding to the extra-cellular domain of the human EGF receptor of said cells in an antigen-antibody complex wherein said antibody is produced by hybridoma cell lines ATCC HB 9763 or 9764, each of which provides as a component of the supernatant of its growth medium the highly specific monoclonal antibody 96 and 108, respectively.
  • This invention further relates to a method of producing the monoclonal antibody of the invention which binds to the extracellular domain of a human EGF receptor and which is capable of inhibiting the growth of human cancer cells that express human EGF receptors and are mitogenically stimulated by EGF which comprises the steps of: (i) immunizing mice with a cell expressing human EGF receptor; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to human EGF receptor; (vi) selecting and cloning a hybridoma producing antibody which binds to the extra-cellular domain of a
  • the invention also provides a method of producing the monoclonal antibody of the invention which omits step (vii) described above and contains the further steps: (viii) transferring said clones intraperitoneally into mice; and (ix) harvesting the malignant ascites or serum from said mice, which ascites or serum contains the desired antibody.
  • the invention still further relates to a therapeutic composition
  • a therapeutic composition comprising a pharmaceutical carrier in association with an effective amount of either one of the novel monoclonal antibodies to inhibit the growth of human tumor cells that express human EGF receptors and are mitogenically stimulated by human EGF.
  • Applicant has also surprisingly discovered that the combined treatment of one of the novel monoclonal antibodies with anti-neoplastic drugs such as doxorubicin or cisplatin provides a more efficient treatment for inhibiting the growth of human cancer cells that express human EGF receptors and are mitogenically stimulated by human EGF than the use of the novel monoclonal antibody of the anti-neoplastic agent by itself.
  • the combined treatment using applicant's novel monoclonal antibodies is advantageous because it combines two anti-cancer agents, each operating via a different mechanism of action to yield a cytotoxic effect to human tumor cells.
  • the anti-neoplastic agent can be administered at levels substantially lower than the levels required when administering the anti-neoplastic agent by itself, which are toxic or subtoxic to the patient.
  • Anti-neoplastic agents other than doxorubicin or cisplatin such as bleomycin sulfate, carmustine, chlorambucil, and cyclophosphamide hydroxyurea may also be used with the novel monoclonal antibody.
  • doxorubicin or cisplatin such as bleomycin sulfate, carmustine, chlorambucil, and cyclophosphamide hydroxyurea
  • This invention also provides a method for inhibiting the growth of human tumor cells that express human EGF receptors and are mitogenically stimulated by human EGF which comprises administering an effective amount of an anti-neoplastic agent and an effective amount of either one of the novel monoclonal antibodies to a human cancer patient having said tumor cells, whereby the antibody binds to the extra-cellular domain of the human EGF receptor of the tumor cell in an antigen-antibody complex.
  • Figure 1 demonstrates a sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the F(ab)′2 and F(ab) preparations of 108 monoclonal antibody.
  • the gel was run under non-reducing conditions a) intact 108 monoclonal antibody, b) unpurified F(ab)′ 2′ fragment preparation, c) purified F(ab)′ 2′ d) Fab fragment, e) Molecular weight markers, KD.
  • Figure 2 demonstrates competitive binding of 125I 108 monoclonal antibody and its fragments with EGF to KB cells.
  • KB cells were incubated in the presence of 3x10 ⁇ 9M 125I 108 monoclonal antibody (1x106 cpm/ml) in the presence of different concentrations of EGF ( ⁇ ), unlabelled 108 monoclonal antibody ( ⁇ ), its F(ab)′ 2′ fragment ( ⁇ ) or Fab′ fragment ( ⁇ ). (Average of 3 independent measurements).
  • Figure 3 demonstrates a cell sorter analysis of the binding of 108 monoclonal antibody to KB cells.
  • Figure 4 demonstrates the homing of 125I 108 monoclonal antibody to KB cells implanted in nude mice.
  • Figure 5 demonstrates the effect of EGF and 108 monoclonal antibody on colony formation of KB cells. Colony formation assay was carried out at described in Materials and methods in the presence of different concentrations of EGF ( ⁇ ). 108 monoclonal antibody ( ⁇ ).
  • Figure 6 demonstrates the antitumor activity of 108 monoclonal antibody and its fragments against KB cells implanted in nude mice. Each group contained at least six mice. Mice were treated intravenously at days 1, 5, 12, and 18 after tumor inoculation with 1 mg of 108 monoclonal antibody ( ⁇ ), 1 mg monoclonal antibody to DNP ( ⁇ ), 0.66 mg F(ab)′ 2′ ( ⁇ ) or Fab′ ( ⁇ ) fragments of 108 monoclonal antibody. A single 2 mg 108 monoclonal antibody treatment one day after tumor cells injection ( ⁇ ).
  • Figure 7 demonstrates antitumor activity of 108 mAb against KB cells implanted intraperitoneally in nude mice. Seven mice were treated intravenously at days 1, 4, and 7 after tumor inoculation with 0.5 mg of 108 monoclonal antibody (---) or antibody to DNP ( ⁇ ) (8 mice).
  • Figure 8 demonstrates antitumor activity of 108 mAb against KB cells injected intravenously to nude mice.
  • Mice were treated intravenously with 0.5 mg of 108 monoclonal antibody at days 6, 9, and 13 after tumor inoculation. Each point represents analysis of serial sections taken at different depths through the lungs of animals.
  • Figure 9 demonstrates antitumor activity of 108 mAb in combination with doxorubicin against KB cells implanted subcutaneously.
  • Four doses of .45 mg of 108 monoclonal antibody of 37.5 ug of doxorubicin were given 24 hours after the tumor injection and repeated 3 times at 3-4 day intervals.
  • Figures 10 and 11 demonstrate antitumor activity of 108 mAb in combination with cisplatin against KB cells implanted subcutaneously.
  • one treatment comprising 1.8 mg 108 monoclonal antibody and 100 ug cisplatin was administered.
  • mice were treated intravenously a single time 20 hours after the tumor implantation.with 19 mg of 108 monoclonal antibody and 0.1 mg cisplatin (Abic, Ramat-Gan, Israel).
  • PBS ⁇
  • monoclonal antibody ⁇
  • cisplatin ⁇
  • monoclonal antibody + cisplatin ⁇
  • Figure 12 demonstrates the effect of EGF on cell growth.
  • Figure 13 demonstrates anti-EGF receptor antibody (aEGPR) inhibition of anchorage dependent cell growth.
  • 184A1N4 (A and B) and MDA-468 (C and D) cells were passed (5,000/well) into triplicate wells of 24-well plates and allowed to attach before antibody was added.
  • 184A1N4 growth media contained 1 ng/ml EGF. Growth media was changed after 48 h and the cells were counted after 4 days. Data is % control cell numbers (mean ⁇ SD).
  • Figure 14 demonstrates reversal of aEGFR inhibition of anchorage dependent cell growth by EGF.
  • Cells were passed (5,000/well) into triplicate wells of 24-well plates.
  • 184A1N4 cells (A and B) were allowed to attach for 4 h in medium containing no EGF before the addition of EGF and antibodies.
  • MDA-468 cells (C and D) were allowed to attach overnight.
  • Antibodies were added for a final concentration of 20nM.
  • Media was changed after 48 h and cells were counted after 4 days. Data are mean ( ⁇ SD) cell numbers.
  • Figure 15 demonstrates inhibition of 184A1N4-T colony formation by monoclonal aEGFR.
  • Cells were grown in soft agar as described in Example VIII(B) in the presence of 20nM aEGFR or 20nM non-specific antibodies and increasing concentrations of EGF. Data are mean ( ⁇ SD) number of colonies greater than 60 um in size.
  • Figure 16 demonstrates the effects of aEGFR on MDA-468 colony formation.
  • Cells were grown in soft agar as described in Example VIII(C) in the presence of 20 nM aEGFR or non-specific antibody and increasing concentrations of EGF. Cells were also grown in the presence of EGF alone. Data are mean ( ⁇ SD) number of colonies greater than 60 um in size.
  • Figure 17 demonstrates the effects of aEGFR on [125I]EGF binding to MDA-468 cells.
  • Confluent MDA-468 cells in 24-well plates were incubated at 4°C for 2.5 h with iodinated EGF (1 nM) and increasing concentrations of unlabeled antibody or EGF.
  • Data are the means ( ⁇ SD) of duplicate determinations from 2 or 3 separate experiments.
  • CH 71 cells are chinese hamster ovary cells which have been transfected with a plasmid bearing a truncated form (deletion of most of the intracellular domain of the EGF-R) of the EGF-R cDNA (Livneh, et al ., J. Biol. Chem. , Vol. 260, 12490 (1986)). These transfected cells express approximately 106 mutant EGF-R molecules/cell.
  • the choice of CH-71 cells allows the selection in the first screening test of only hybridomas secreting antibodies against the extracellular domain of the EGF-R and avoids the selection of antibodies directed against the human specific carbohydrates linked to the human EGF-R molecule.
  • mice were immunized three times on day 0, 13, and 32.
  • the two best responding mice were each boosted by three intraperitioneal injections of CH 71 cells three consecutive days before the fusion.
  • the spleen cells of the mice were then fused with NS1 myeloma cells (ratio 5/1) according to the general procedure of Kohler and Milstein, using PEG 4000 (Merck) as the fusing agent. (Kohler and Milstein, Eur. J. Immun., Vol. 6, 511-519, 1976).
  • the fusion product was diluted in hypoxanthineazaserine (HA) selection medium (G. Buttin, et al ., Current Topics in Microbiology and Immunology, Vol. 81, 27-36, (1978)) instead of the hypoxanthine-aminopterin-thymidine (HAT) selection medium and distributed in 96 well plates.
  • HA hypoxanthineazaserine
  • the presence of specific antibodies in the medium of the wells of the growing hybridoma cells was first assayed by radioimmunoassay.
  • Cells expressing or not expressing the EGF receptor were plated in 96 well plates. At confluency, they were washed once with binding medium (DMEM, 20 mM Hepes, 0.2% BSA) and incubated for 90 min at room temperature with 100 ul of culture supernatant from the different growing hybridomas. Cells were then washed 3 times with binding medium and incubated for a further 60 min at room temperature with 100 ul of a solution of iodinated goat antimouse immunoglobulins (250,000 cpm/100 ul).
  • binding medium DMEM, 20 mM Hepes, 0.2% BSA
  • the cells were scraped from the wells and the radioactivity which was associated with their surface was counted using a gamma counter.
  • the ability of the antibodies to bind specifically to the surface of cells expressing the EGF receptor was measured in this way and compared to their ability to bind to cells that do not express the EGF-R (a particular clone of mouse 3T3 cells).
  • the positive hybridomas were cloned by limiting dilution and further tested by measuring their ability to immunoprecipitate 35S methionine or 32P labeled EGF-R from lysates of cell lines of different species (human, mouse, chicken). For this, goat antimouse immunoglobulins were bound to Protein A-Sepharose by incubation of goat antimouse antibody solution with Protein A-Sepharose beads for 30 min at room temperature. This was followed by washing 3 times with 20 mM Hepes, pH 7.4.
  • the goat mouse Ig′s coated Protein A-Sepharose beads were further incubated for 30 min at room temperature with the culture supernatant of the hybridomas, washed 3 times with HNTG buffer (20 mM Hepes , 150 mM NaCl, 0.1% Triton X-100, 10% glycerol) and incubated for 1 hour at 4 degrees C with the different cell lysates obtained by lysing cell monolayers with solubilization buffer (1% Triton X-100, 150mM NaCl, 20 mM Hepes, 1.5 mM EGTA, 1.5 mM Mg Cl2, 10% glycerol, aprotinin, leupeptin and PMSF as protease inhibitors) and centrifugation of the lysate to discard the nuclear pellet.
  • HNTG buffer 20 mM Hepes , 150 mM NaCl, 0.1% Triton X-100, 10% glycerol
  • the immunoprecipitates were washed with HNTG 3 times and then incubated for 15 min with a 32P ATP solution (HNTG with 5 mM MnCl2 and 3 uCi/sample of 32P ATP). Electrophoresis sample buffer was then added and the samples boiled for 10 min at 95 degrees C prior loading on a 7.5% SDS-polyacrylamide gel.
  • Monoclonal antibodies 108, 96 and 42 were all found to be specific for the human EGF-R. These antibodies were also tested for their ability to inhibit the binding of iodinated EGF to the surface of cells expressing EGF-R. These 3 antibodies inhibit the binding of EGF to its receptor, but the level of inhibition varied with 96 > 108 > 42.
  • the KB tumor cell line derived from oral epidermoid carcinoma was obtained from the American Type Tissue Culture Collection. The cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum depleted of complement activity by incubation at 56°C for 30 min and grown in glutamine, penicillin, streptomycin and sodium pyruvate, at 37°C in 5% CO2: 95% air atmosphere.
  • 184A1N4 and 184A1N4-T human mammary epithelial cells were provided by Martha Stampfer, Lawrence Berkeley Laboratory, Berkeley, CA.
  • 184A1N4 cells were maintained at 37°C in 5% CO2 and IMEM supplemented with glutamine (0.6 mg/ml), fetal calf serum (0.5%), hydrocortisone (0.5 ug/ml), insulin (5 ug/ml) and EGF (10 ng/ml).
  • 184A1N4-T were maintained at 37°C in 5% CO2 in IMEM (Biofluids, Rockville, MD) supplemented with glutamine (0.6 mg/ml), gentamicin (40 mg/ml) and 10% fetal calf serum.
  • MDA-468 cells were cultured under the same conditions and medium as 184A1N4-T cells.
  • the 108 IgG2a hybridoma cell line was generated by immunizing mice with CH 71 cells expressing the EGF receptor and cultured under the same conditions as the KB cell line.
  • the 96 IgM hybridoma cell line was generated by the same procedure as that described for the 108 IgG2a hybridoma cell line.
  • This material was semi-purified by gel filtration using Sephacryl S-3000 equilibrated in 50 mM Tris, pH 7.8, 0.5 M NaCl. The peak containing the mAb96 antibody was pooled and dialyzed against PBS.
  • the F(ab)′2 (2 mg/ml) was reduced by 10 mM dithiothreitol in 20 mM Tris buffer, pH 8.2, for 1 h at 37°C. Alkylation was performed in 40 mM iodoacetamide for 30 min at 37°C, followed by extensive dialysis against PBS at 4°C. Purity and complete digestion of the various fragments were analyzed by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE, see Figure 1).
  • 125I-labeling of 108 monoclonal antibody was performed by the chloramine T method (Hunter and Greenwood, Preparation of 131Iodine Labelled Human Growth Hormone of High Specific Activity, Nature , Vol. 196, 465-6, (1962)). Specific activities of about 3X106 cpm/ug IgG were usually obtained.
  • the F(ab) ′ 2 and F(ab) fragments of 108 monoclonal antibody were fully immunoreactive when compared to native intact 108 monoclonal antibody in their capacity to compete with the binding of 125-I labeled 108 to EGF receptors exposed on KB cells (See Figure 2).
  • the antibody binding activity of 108 hybridoma supernatant was determined by an indirect immunofluorescence assay.
  • KB cells (2X106 per sample) were trypsinized 24 hours before the assay and placed in test tubes (Falcon, polystyrene round bottom tubes). Prior to assay, the KB cell suspensions were washed with cold PBS and incubated with 108 hybridoma supernatant for 45 min at 4°C. After washing with PBS containing 1% bovine serum albumin, the cells were incubated with fluorescein-labeled rabbit anti-mouse IgG for 45 min at 4°C. Cell samples were suspended in PBS and analyzed by a fluorescence cell sorter (FACS II, Bectin Dickenson, Mountainview, Ca, USA). (See Figure 3.)
  • KB cells (105/well in 24 well plates; NUNC) were grown for 24 hours, washed with PBS and incubated with different concentrations of either native antibody or its fragments in DMEM containing 1% bovine serum albumin for 1 h at 4°C, or at room temperature, in the presence of 125I 108 monoclonal antibody (about 1X106 cpm/ml). The cells were then washed, solubilized in 0.5 N NaOH and their radioactivity was determined in a counter (Kontron, Switzerland). Non-specific binding was determined by the addition of 100-fold excess of unlabelled monoclonal antibody. Results are presented as the percentage of radioactivity associated with the cells incubated with unlabelled antibody (intact or fragmented) vs. radioactivity associated with cells incubated without the addition of cold antibody.
  • EGF competes with the binding of the antibody to the receptor to a maximal level of about 70% (See Figure 2).
  • KB cells (4 x 106) were inoculated subcutaneously on the back of nude mice (5-6 weeks old). After 14 days, when the tumor reached a diameter of about 1.2 cm, 125I 108 monoclonal antibody was injected intravenously or intraperitoneally (5X106 cpm; 3X106 cpm/ug). 125I-7H01 monoclonal antibody to human hepatitis B virus IgG2a served as control. Four days after the administration of antibodies, animals were killed and the radioactivity in the different tissues was determined. Means of at least four animals per group are presented. (See Figure 4)
  • Both intravenous and intraperitioneal administration of the tagged 108 monoclonal antibody resulted in antibody concentration at the tumor mass.
  • Administration of control IgG resulted in no concentration at the tumor mass when given intravenously, while a marginal concentration in the tumor was detected when the antibodies were administered intraperitoneally.
  • the percentage of injected dose accumulated at the tumor mass 96 h post intravenal injection were 7.8 ⁇ 1.1 and 0.8. ⁇ 0.1 for monoclonal antibody 108 and 7H01 monoclonal antibody (control antibody) respectively, and for the intraperitioneal injection 7.5 ⁇ 0.4 and 1.8 ⁇ 0.2 respectively.
  • Washed, confluent MDA-468 cell monolayers in 24-well culture plates were incubated at 4°C for 2.5 h with or without various concentrations of antibody or unlabeled EGF in binding buffer (IMEM, 0.1% BSA, 50 mM Hepes) [125I]EGF (S.A. 80-160 uCi/ug, ICN Radiochemicals, CA) was added for a final concentration of 1 nm. After incubation the monolayers were washed, solubilized with lysis buffer (10 mM Tris, 1 mM EDTA, 0.5% SDS, pH 7.4) and radioactivity was determined using a gamma-counter (LKB-Pharmacia).
  • lysis buffer (10 mM Tris, 1 mM EDTA, 0.5% SDS, pH 7.4
  • KB cells were seeded in petri dishes (50 x 15 nM2, NUNC) at a concentration of 2 x 102 cells per dish. After 16 to 24 h medium was replaced with a fresh one containing different concentrations of either native or fragmented 108 monoclonal antibody with or without EGF. On the sixth day cultures were refed by fresh medium containing the above ingredients. On the 15th day the cultures were washed with PBS, fixed with 4% v/v formaldehyde in PBS for 15 min and stained with hematoxylin. Number of formed colonies (25 cells) was then determined.
  • Figure 4 shows the effect of increasing concentrations of EGF and 108 monoclonal antibody on the growth of KB cells.
  • Exposure of KB cells to EGF 160 nM resulted in an increase to 150% in the number of colonies counted 15 days after seeding (14 days after the beginning of the treatment) as compared to cells incubated in the absence of growth factor.
  • EGF caused an increase in the size of KB cell colonies.
  • 108 monoclonal antibody 1.6 uM
  • the number of cell colonies was reduced to 30% of control values.
  • a 100-fold excess of 108 monoclonal antibody added together with EGF given at concentration which caused a 50% increase in the colony number reduced the number of colonies to 20% of control values.
  • F(ab)′2 fragments of 108 monoclonal antibody had no effect on the number of KB colonies. Yet when added in 100-fold excess to EGF, the F(ab)′2 fragments are able to abolish the effect of EGF on the number of formed colonies (from 150% to 103%). Incubation with the same concentration of monoclonal antibody to dinitrophenyl (DNP) did not affect the number of formed colonies. (See Figure 5).
  • KB cells (2X106) were injected subcutaneously into nude mice, followed by either one or several intravenal injections of the 108 monoclonal antibody, starting one day after tumor cell injection.
  • the antibody was assayed for its capacity to inhibit the growth of KB cells in nude mice (See Figure 6). Animals received 1 mg of either 108 monoclonal antibody or control monoclonal antibody to dinitrophenyl at days 1, 5, 12 and 18 after tumor inoculation. The fragments F(ab)′2 and Fab′ were given at antibody equivalent doses.
  • the 108 monoclonal antibody-treated group significantly retarded tumor development and growth when compared to the group treated with control monoclonal antibody (P ⁇ 0017, student-t test).
  • the F(ab)′ 2′ was found to affect tumor growth but less efficiently than the whole antibody (P ⁇ 0.05 student-t test for days 12, 17, 22, 25). Fab′ fragment did not affect the tumor growth.
  • a single 2 mg does of 108 native monoclonal antibody given one day after injection of tumor cells was found to be as efficient as four treatments of 1 mg given at days 1, 5, 12 and 18 after tumor inoculation.
  • the antitumoral effect was slightly lower, yet a significant difference between the control and the treated group was found using the Mann Whitney analysis (p ⁇ 0.03 for days 9, 12, 14, 17) and student-t test (p ⁇ 0.05 days 9, 12).
  • the correlation coefficient between the tumor volume and the tumor weight was 0.95 (P ⁇ 0.0001).
  • mice The injection of 3 x 106 KB cells intraperitoneally one week after mice (Nude in general background) received x-irradiation (400 rads), brought about the development of an ascitic growth.
  • the intraperitioneal tumor-bearing mice died after 30 days.
  • Three intravenous injections of 108 monoclonal antibody (.5 mg each) prolonged the life span of animals with 30% of animals not developing tumors at all. (See Figure 7).
  • the metastatic form of the KB tumor could be obtained by the injection of the cells intravenously (i.v.). Mice injected with 1.5x106 KB cells developed tumor nodules in the lungs 4-6 weeks after their implantation. This tumor model mimics the situation in the clinic, where tumor cells infiltrate into internal organs. This is the major problem in the treatment of cancer.
  • the KB cell injection was followed by 3 intravenous injections of .5 mg 108 monoclonal antibody at days 6, 9, and 13 after the tumor cell injection. At the termination of the experiment, the lungs were removed, fixed in 4% formaldehyde and paraffin embedded. Serial sections were cut 4-5 um in thickness and stained with hematoxylin.
  • the number of metastatic nodules of various depths through the lungs was obtained by light microscopy analysis. Isolation of three metastatic cell clones from lungs of tumor bearing animals and their assay for receptor levels revealed persistence of receptor expression. Treatment by the antibody reduced the number of lung tumor nodules to 15% of those in the respective controls. (P ⁇ 0.05 Mann-Whitney analysis) (See Figure 8).
  • 184A1N4 and MDA-468 cells were passed (5,000/well) into triplicate wells of 24-well plates and allowed to attach before antibody was added.
  • 184A1N4 growth media contained 1 ng/ml EGF and differing amounts of EGFR antibody which was added to the growth media simultaneously with the EGF.
  • MDA-468 growth media contained no EGF. Growth media was changed after 48 h and the cells were counted after 4 days. At the end of the experimental growth period cells were harvested with trypsin-EDTA and counted using a Particle Data cell counter (Particle Data, Inc., Elmhurst, IL). Data is % control cell numbers (mean ⁇ SD).
  • 184A1N4-T cells were suspended in semisolid agar medium containing 0.4% Bacto-Agar (Difco, Detroit, MI), IMEM, 10% FBS and treatments. Cells were plated (10,000/dish) into triplicate 35 mm culture dishes containing 1 ml IMEM, 0.6% agar and 10% FBS. The dishes were incubated for 10-14 days at 37°C in 5% CO2 in the presence of 20 nM aEGFR or 20 nM nonspecific antibodies and increasing concentrations of EGF. Data are mean ( ⁇ SD) number of colonies greater than 60 um in size.
  • IgM 96 IgM( ⁇ ), 42 IgM( ⁇ ), nonspecific IgM( ⁇ ). Cell colonies larger than 60 um in diameter were counted using a Bausch & Lomb colony counter (See Figure 15).
  • MDA-468 cells were suspended in semisolid agar medium containing 0.4% Bacto-Agar (Difco, Detroit, MI) IMEM, 10% FBS and treatments. Cells were plated (10,000/dish) into triplicate 35 mm culture dishes containing 1 ml IMEM, 0.6% agar and 10% FBS. The dishes were incubated for 10-14 days at 37°C in 5% CO2 in the presence of 20 nM aEGFR or 20 nM nonspecific antibodies and increasing concentrations of EGF. Data are mean ( ⁇ SD) number of colonies greater than 60 um.
  • IgM 96 IgM( ⁇ ), 42 IgM( ⁇ ), nonspecific IgM( ⁇ ) EGF alone ( ⁇ ). Cell colonies larger than 60 nm in diameter were counted using a Bausch & Lomb colony counter. (See Figure 16).
  • Monoclonal antibody 108 was injected to form a subcutaneous tumor. Four doses of .45 mg of 108 monoclonal antibody and 37.5 ug of doxorubicin (adriamycin) were given 24 h after the tumor injection and repeated 3 times at 3-4 day intervals. The volume of the tumor was compared to the controls: phosphate buffered saline, antibody alone or drug alone. (See Figure 9).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)
  • Supplying Of Containers To The Packaging Station (AREA)
  • Meat, Egg Or Seafood Products (AREA)

Claims (9)

  1. Anticorps monoclonal qui inhibe la croissance des cellules tumorales humaines par le fait que ledit anticorps se lie au domaine extracellulaire des récepteurs de EGF humain desdites cellules tumorales en un complexe antigène-anticorps, lesdites cellules tumorales étant caractérisées par leur expression de récepteurs de EGF humain et leur stimulation mitogène par EGF humain, et ledit anticorps ayant la capacité d'inhiber la croissance des cellules de carcinome épidermoïde oral humain (KB) ou des cellules épithéliales mammaires humaines (184) en se liant au domaine extracellulaire du récepteur de EGF humain desdites cellules en un complexe antigène-anticorps, ledit anticorps étant l'anticorps 108 produit par la lignée cellulaire d'hybridome ATCC HB 9764 ou l'anticorps 96 produit par la lignée cellulaire d'hybridome ATCC HB 9763.
  2. Lignée cellulaire d'hybridome qui produit l'anticorps monoclonal de la revendication 1.
  3. Procédé de production de l'anticorps monoclonal selon la revendication 1, qui comprend les étapes consistant à
    (i) immuniser des souris avec une cellule exprimant un récepteur de EGF humain;
    (ii) retirer les rates desdites souris et former une suspension des cellules spléniques;
    (iii) fusionner lesdites cellules spléniques avec des cellules de myélome de souris en présence d'un promoteur de fusion;
    (iv) diluer et cultiver les cellules fusionnées dans des puits séparés dans un milieu qui ne favorise pas les cellules de myélome non fusionnées;
    (v) évaluer le surnageant dans chaque puits contenant un hybridome en ce qui concerne la présence d'un anticorps dirigé contre un récepteur de EGF humain;
    (vi) sélectionner et cloner un hybridome produisant un anticorps qui se lie au domaine extracellulaire d'un récepteur de EGF humain; et
    (vii) récupérer l'anticorps à partir du surnageant situé au-dessus desdits clones.
  4. Procédé selon la revendication 3, dans lequel l'étape (vii) est omise et ledit procédé comprend en outre les étapes consistant à
    (viii) transférer lesdits clones par voie intrapéritonéale dans des souris ; et
    (ix) récolter l'ascite maligne ou le sérum malin desdites souris, laquelle ascite ou lequel sérum contient l'anticorps voulu.
  5. Composition thérapeutique contenant un anticorps monoclonal selon la revendication 1 et éventuellement en plus un véhicule pharmaceutiquement acceptable.
  6. Composition thérapeutique selon la revendication 5, comprenant une quantité dudit anticorps monoclonal efficace pour inhiber la croissance des cellules tumorales humaines qui expriment des récepteurs de EGF humain et qui sont stimulées du point de vue de la mitogenèse par le EGF humain, en association avec un véhicule pharmaceutique.
  7. Composition thérapeutique selon la revendication 5 ou 6, qui contient en outre un agent antinéoplasique.
  8. Composition thérapeutique selon la revendication 7, dans laquelle ledit agent antinéoplasique est la doxorubicine ou le cisplatine.
  9. Procédé pour préparer la composition thérapeutique selon l'une quelconque des revendications 5 à 8 qui comprend la combinaison de l'anticorps monoclonal selon la revendication 1 et d'un véhicule pharmaceutiquement acceptable et éventuellement d'un agent antinéoplasique.
EP89117125A 1988-09-15 1989-09-15 Anticorps monoclonaux spécifiques du récepteur du facteur de la croissance de l'épiderme humain et compositions thérapeutiques les contenant Expired - Lifetime EP0359282B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP94117268A EP0667165B1 (fr) 1988-09-15 1989-09-15 Compositions thérapeutiques contenant des anticorps monoclonaux contre le récepteur humain du facteur de croissance épidermique
LU91117C LU91117I2 (en) 1988-09-15 2004-10-29 Cetuximab in combination with irinotecan.
LU91116C LU91116I2 (fr) 1988-09-15 2004-10-29 Cetuximab
NL300166C NL300166I1 (nl) 1988-09-15 2004-12-13 Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijke epidermale groeifactorreceptor.
NL300167C NL300167I1 (nl) 1988-09-15 2004-12-13 Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijke epidermale groeifactorreceptor.
NL300351C NL300351I1 (nl) 1988-09-15 2008-05-28 Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor
NL300350C NL300350I1 (nl) 1988-09-15 2008-05-28 Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor
LU91449C LU91449I2 (fr) 1988-09-15 2008-05-29 "panitumumab en combinaison avec un agent anti-néoplastique"
LU91448C LU91448I2 (fr) 1988-09-15 2008-05-29 "panitumumab"
NL300353C NL300353I1 (nl) 1988-09-15 2008-06-03 Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24473788A 1988-09-15 1988-09-15
US244737 1988-09-15
US31910989A 1989-03-03 1989-03-03
US319109 1989-03-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP94117268A Division EP0667165B1 (fr) 1988-09-15 1989-09-15 Compositions thérapeutiques contenant des anticorps monoclonaux contre le récepteur humain du facteur de croissance épidermique
EP94117268.6 Division-Into 1994-11-02

Publications (3)

Publication Number Publication Date
EP0359282A2 EP0359282A2 (fr) 1990-03-21
EP0359282A3 EP0359282A3 (en) 1990-05-23
EP0359282B1 true EP0359282B1 (fr) 1995-05-24

Family

ID=26936756

Family Applications (2)

Application Number Title Priority Date Filing Date
EP89117125A Expired - Lifetime EP0359282B1 (fr) 1988-09-15 1989-09-15 Anticorps monoclonaux spécifiques du récepteur du facteur de la croissance de l'épiderme humain et compositions thérapeutiques les contenant
EP94117268A Expired - Lifetime EP0667165B1 (fr) 1988-09-15 1989-09-15 Compositions thérapeutiques contenant des anticorps monoclonaux contre le récepteur humain du facteur de croissance épidermique

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP94117268A Expired - Lifetime EP0667165B1 (fr) 1988-09-15 1989-09-15 Compositions thérapeutiques contenant des anticorps monoclonaux contre le récepteur humain du facteur de croissance épidermique

Country Status (10)

Country Link
US (1) US6217866B1 (fr)
EP (2) EP0359282B1 (fr)
JP (3) JP3600617B2 (fr)
AT (2) ATE214943T1 (fr)
AU (1) AU4128089A (fr)
CA (1) CA1340417C (fr)
DE (7) DE122004000041I1 (fr)
ES (2) ES2075019T3 (fr)
LU (4) LU91117I2 (fr)
NL (5) NL300167I1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556285A1 (fr) * 1990-11-05 1993-08-25 Bristol-Myers Squibb Company Therapie synergique par combinaisons d'anticorps anti-tumeur avec des agents biologiquement actifs
US5770195A (en) * 1988-01-12 1998-06-23 Genentech, Inc. Monoclonal antibodies directed to the her2 receptor
US6123939A (en) * 1989-08-04 2000-09-26 Berlex Laboratories, Inc. Anti-neoplastic drugs in cancer therapy
EP1080113A1 (fr) 1998-05-15 2001-03-07 Imclone Systems, Inc. Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20080096236A1 (en) * 1998-08-25 2008-04-24 Binax, Inc. Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
IL146480A0 (en) * 1999-05-14 2002-07-25 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
TWI269654B (en) 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US20020103345A1 (en) * 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
EP1170011A1 (fr) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Nouvelle utilisation des inhibiteurs de facteur de croissance épidermique
AU2001295002B2 (en) * 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
DE60134679D1 (de) * 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
JP4660067B2 (ja) 2001-04-24 2011-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血管新生剤とＴＮＦαとを用いる組合せ療法
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
KR20090125840A (ko) * 2001-06-13 2009-12-07 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간 모노클로날 항체
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2452058A1 (fr) * 2001-06-26 2003-01-09 Imclone Systems Incorporated Anticorps bispecifiques se liant aux recepteurs vegf
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2004058821A2 (fr) * 2002-12-27 2004-07-15 Domantis Limited Ligand
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
DK1916001T3 (da) 2002-03-04 2011-07-18 Imclone Llc KDR-specifikke humane antistoffer og anvendelser deraf
AU2003211594A1 (en) * 2002-03-05 2003-09-16 Eisai Co., Ltd. Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
ATE328906T1 (de) * 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
ES2533963T3 (es) * 2002-10-10 2015-04-16 Merck Patent Gmbh Composiciones farmacéuticas dirigidas a receptores Erb-B1
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
EP1622941A2 (fr) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Procede de production d'un anticorps contre le recepteur du facteur de croissance epidermique
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
US20070036795A1 (en) 2003-06-09 2007-02-15 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
CN104059147A (zh) 2003-06-27 2014-09-24 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
JP4303726B2 (ja) * 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
PL1735348T3 (pl) 2004-03-19 2012-11-30 Imclone Llc Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
NZ550665A (en) 2004-04-09 2010-05-28 Chugai Pharmaceutical Co Ltd Novel water-soluble prodrugs of camptothecin derivatives
AU2005265163B2 (en) 2004-06-18 2009-10-01 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US8772269B2 (en) * 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
WO2006042313A2 (fr) * 2004-10-12 2006-04-20 Imclone Systems Incorporated Methode de traitement destinee a combattre l'accumulation de liquide sereux dans des cavites sereuses du corps
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
JPWO2006090930A1 (ja) * 2005-02-28 2008-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の新規併用
US20060233810A1 (en) * 2005-04-15 2006-10-19 Yaolin Wang Methods and compositions for treating or preventing cancer
US20090214562A1 (en) * 2005-05-03 2009-08-27 Karel Steven J Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
CA2611149A1 (fr) 2005-06-15 2006-12-28 Schering Corporation Formulation d'anticorps stable
CA2678008C (fr) 2005-06-17 2013-07-30 Imclone Systems Incorporated Antagonistes de recepteur pour le traitement de cancer osseux metastatique
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
JP2007039346A (ja) * 2005-08-01 2007-02-15 Yokohama Kokusai Bio Kenkyusho:Kk 腫瘍特異的抗体と結合したタキソイド誘導体及びその製造方法
EP1925676A4 (fr) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Procédé d'analyse de l' effet d 'un inhibiteur de vascularisation
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2620594C (fr) * 2005-09-01 2012-08-21 Eisai R&D Management Co., Ltd. Composition pharmaceutique dotee d'une meilleure capacite a se desintegrer
EP1934599A1 (fr) 2005-10-11 2008-06-25 Merck Patent GmbH Modulation dépendante d'egfr de l'expression des chimiokines et influence sur le traitement et le diagnostic des tumeurs et sur leurs effets secondaires
CN101316590B (zh) * 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
US20090306101A1 (en) * 2005-11-11 2009-12-10 Flavio Solca Combination treatment of cancer comprising egfr/her2 inhibitors
US8404697B2 (en) 2005-11-11 2013-03-26 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
EP1964837A4 (fr) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Agent antitumeur pour myelomes multiples
EA200801170A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
EA015173B1 (ru) 2006-01-04 2011-06-30 Мерк Патент Гмбх Комбинированная терапия с использованием антител к egfr и her2
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
CA2650953A1 (fr) 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combinaison d'un anticorps l19-sip anti domaine ed-b de la fibronectine et d'un anticorps anti-egfr
ES2556173T3 (es) * 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
EP2044939A1 (fr) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
CA2655997A1 (fr) 2006-06-30 2008-01-10 Schering Corporation Biomarqueur igfbp2
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
MX338185B (es) * 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
EP2119707B1 (fr) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
WO2008104183A2 (fr) * 2007-03-01 2008-09-04 Symphogen A/S Compositions d'anticorps recombinants dirigés contre le récepteur du facteur de croissance épidermique
CN101679511A (zh) * 2007-06-06 2010-03-24 杜门蒂斯有限公司 多肽、抗体可变域和拮抗剂
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
US20100322939A1 (en) * 2007-06-21 2010-12-23 Genmab A/S Novel methods for treating egfr-associated tumors
EP2188311B1 (fr) * 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Anticorps monoclonal 175 ciblant le récepteur egf et dérivées et utilisations de ceux-ci
EP3492488A1 (fr) 2007-08-22 2019-06-05 The Regents of The University of California Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci
CA2715080C (fr) 2007-09-28 2021-09-28 Intrexon Corporation Constructions et bioreacteurs de commutation de gene theapeutique destines a l'expression de molecules biotherapeutiques, et utilisation de ceux-ci
EP2212432A4 (fr) * 2007-10-22 2011-10-19 Schering Corp Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
AU2009210098B2 (en) * 2008-01-29 2013-06-13 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
ES2639857T3 (es) 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
CA2716851A1 (fr) * 2008-03-06 2009-09-11 Genentech, Inc. Therapie combinee par des antagonistes de c-met et egfr
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
AU2009287163B2 (en) 2008-08-29 2014-11-13 Les Laboratoires Servier Recombinant anti-Epidermal Growth Factor Receptor antibody compositions
EP3216874A1 (fr) * 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Procédés pour la stratification et l'annotation des options de traitement médicamenteux contre le cancer
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
SG174378A1 (en) 2009-03-20 2011-10-28 Genentech Inc Bispecific anti-her antibodies
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US20120288495A1 (en) 2009-07-22 2012-11-15 Biothera, Inc. Therapeutic compositions and methods
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AU2010310786B2 (en) 2009-10-23 2014-03-27 Eli Lilly And Company AKT inhibitors
WO2011107664A1 (fr) 2010-03-04 2011-09-09 Hospital District Of Southwest Finland Méthode de sélection de patients pour un traitement par un inhibiteur de l'egfr
EP2371369A1 (fr) 2010-04-01 2011-10-05 Institut Gustave Roussy (IGR) Inhibiteur EGFR et agent antiviral pour une utilisation simultanée, séparée ou séquentielle pour le traitement, la prévention et/ou la palliation du cancer
WO2011156617A2 (fr) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anticorps anti-egfr
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012009705A1 (fr) 2010-07-15 2012-01-19 Zyngenia, Inc. Complexes liant ang-2 et leurs utilisations
US9464136B2 (en) 2010-08-20 2016-10-11 Massachusetts Institute Of Technology Antibody-based constructs directed against tyrosine kinase receptors
EP3572528A1 (fr) 2010-09-24 2019-11-27 The Board of Trustees of the Leland Stanford Junior University Capture directe, amplification et séquençage d'adn cible à l'aide d'amorces immobilisées
JP6243737B2 (ja) 2010-10-27 2017-12-06 ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク Ｅ−カドヘリンの可溶性細胞外ドメインを標的とする組成物および癌治療のための関連方法
SG189929A1 (en) 2010-10-29 2013-06-28 Immunogen Inc Novel egfr-binding molecules and immunoconjugates thereof
EA201390575A1 (ru) 2010-10-29 2014-01-30 Иммьюноджен, Инк. Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
JP2014503500A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
WO2012144463A1 (fr) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent thérapeutique pour les tumeurs
WO2012166899A2 (fr) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
EP3559049A4 (fr) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Produits de recombinaison de polypeptide et utilisations de ceux-ci
CN104066481A (zh) 2011-11-21 2014-09-24 伊缪诺金公司 利用egfr抗体细胞毒性剂缀合物治疗抗egfr疗法的肿瘤的方法
EP2879712B1 (fr) 2012-07-31 2018-04-25 Crown Bioscience, Inc. (Taicang) Marqueurs histologiques pour l'identification de patients atteints d'un carcinome du poumon non à petites cellules pour le traitement par un médicament anti-egfr
AU2013299841B8 (en) 2012-08-07 2017-01-05 Array Biopharma Inc. Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
MX2015007719A (es) 2012-12-21 2015-09-07 Sykehuset Sørlandet Hf Terapia dirigida del receptor del factor de crecimiento epidermico (egfr) de trastornos neurologicos y dolor.
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
MX2015010427A (es) 2013-02-13 2016-03-17 Lab Francais Du Fractionnement Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos.
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
AU2013388126B2 (en) 2013-04-29 2019-03-07 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
RU2646098C2 (ru) * 2013-04-30 2018-03-01 Интас Фармасьютикалс Лтд Новый способ клонирования, экспрессии и очистки для получения ранибизумаба
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
RU2675824C2 (ru) 2013-09-11 2018-12-25 Игл Байолоджикс, Инк. Жидкие белковые составы, содержащие ионные жидкости
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
RS63559B1 (sr) 2014-08-28 2022-10-31 Eisai R&D Man Co Ltd Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
AU2015341081A1 (en) 2014-10-28 2017-06-08 Merck Patent Gmbh Methods for non-covalent Fc-domain-containing protein display on the surface of cells and methods of screening thereof
KR102639037B1 (ko) 2014-10-29 2024-02-20 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 인터페론 α2b 변이체
CA2963274C (fr) 2014-12-05 2024-01-30 Avidbiotics Corp. Fragments variables inserables d'anticorps et domaines a1-a2 modifies de ligands nkg2d
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
CN105237638A (zh) * 2015-10-26 2016-01-13 无锡傲锐东源生物科技有限公司 抗egfr蛋白单克隆抗体杂交瘤细胞及其产生的抗egfr单克隆抗体和应用
RU2018141777A (ru) 2016-04-28 2020-05-28 Биомюнё Фармасьютикалз Биспецифичные антитела, нацеленные на egfr и her2
HUE060653T2 (hu) 2016-06-03 2023-04-28 Array Biopharma Inc Gyógyászati kombinációk
KR20190019091A (ko) 2016-06-24 2019-02-26 사이포스 바이오사이언시스 인코포레이티드 항체의 삽입가능 가변 단편 및 nkg2d 리간드의 변형된 a1-a2 도메인
EP3525829A1 (fr) 2016-10-11 2019-08-21 Medimmune Limited Conjugués anticorps-médicament associés à des agents thérapeutiques à médiation immunitaire
CN106800599B (zh) * 2016-12-05 2021-03-23 中国人民解放军第二军医大学 抗人EGFR和Notch多特异性抗体、其制备方法及用途
BR112019014127A2 (pt) 2017-02-08 2020-02-11 Eisai R&D Management Co., Ltd. Composição farmacêutica para tratamento de tumores
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CA3019207A1 (fr) 2017-09-28 2019-03-28 The Governing Council Of The University Of Toronto Methodes et compositions empechant le signalement de mutation d'egfr
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
SG11202104900SA (en) 2018-11-20 2021-06-29 Univ Cornell Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
WO2020200944A1 (fr) 2019-03-29 2020-10-08 F. Hoffmann-La Roche Ag Procédé de production d'anticorps multispécifiques à liaison avide
WO2020225552A1 (fr) 2019-05-06 2020-11-12 Medimmune Limited Combinaison de monalizumab, de durvalumab, de chimiothérapie et de bévacizumab ou de cétuximab pour le traitement du cancer colorectal
WO2022079211A1 (fr) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugués
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
AU2022250323A1 (en) 2021-03-31 2023-11-09 Nihon Medi-Physics Co., Ltd. Radioactive complex of anti-egfr antibody, and radiopharmaceutical
CA3222462A1 (fr) 2021-06-14 2022-12-22 Tania Crombet Ramos Utilisation d'anticorps monoclonaux contre le recepteur du facteur de croissance epidermique dans le traitement de patients presentant une insuffisance respiratoire aigue hypoxemiqu
WO2023288267A1 (fr) 2021-07-14 2023-01-19 2Seventy Bio, Inc. Récepteurs de lymphocytes t modifiés fusionnés à des domaines de liaison d'anticorps
WO2023166098A1 (fr) 2022-03-02 2023-09-07 Biomunex Pharmaceuticals Anticorps bispécifiques se liant à her-3 et à her-2 ou egfr
WO2023196997A2 (fr) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Récepteur multipartite et complexes de signalisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770195A (en) * 1988-01-12 1998-06-23 Genentech, Inc. Monoclonal antibodies directed to the her2 receptor
US5772997A (en) * 1988-01-12 1998-06-30 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US6387371B1 (en) 1988-01-12 2002-05-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US6399063B1 (en) 1988-01-12 2002-06-04 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US6123939A (en) * 1989-08-04 2000-09-26 Berlex Laboratories, Inc. Anti-neoplastic drugs in cancer therapy
EP0556285A1 (fr) * 1990-11-05 1993-08-25 Bristol-Myers Squibb Company Therapie synergique par combinaisons d'anticorps anti-tumeur avec des agents biologiquement actifs
EP0556285A4 (en) * 1990-11-05 1993-10-27 Bristol-Myers Squibb Company Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
EP1080113A1 (fr) 1998-05-15 2001-03-07 Imclone Systems, Inc. Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance

Also Published As

Publication number Publication date
US6217866B1 (en) 2001-04-17
DE68929384D1 (de) 2002-05-02
DE122008000027I1 (de) 2009-01-29
JP3732426B2 (ja) 2006-01-05
JP2002114710A (ja) 2002-04-16
EP0667165B1 (fr) 2002-03-27
NL300167I1 (nl) 2005-03-01
ATE214943T1 (de) 2002-04-15
JP4122393B2 (ja) 2008-07-23
LU91449I2 (fr) 2008-07-29
JP2005047934A (ja) 2005-02-24
EP0359282A2 (fr) 1990-03-21
CA1340417C (fr) 1999-03-02
DE122008000030I1 (de) 2008-09-18
JPH02291295A (ja) 1990-12-03
NL300166I1 (nl) 2005-03-01
DE122004000040I1 (de) 2005-02-24
LU91116I2 (fr) 2004-12-29
AU4128089A (en) 1990-03-22
EP0359282A3 (en) 1990-05-23
DE68922808T2 (de) 1995-09-21
LU91117I2 (en) 2004-12-29
DE122008000028I1 (de) 2008-09-18
ATE123070T1 (de) 1995-06-15
EP0667165A1 (fr) 1995-08-16
NL300351I1 (nl) 2008-08-01
DE122004000041I1 (de) 2005-02-24
JP3600617B2 (ja) 2004-12-15
DE68922808D1 (de) 1995-06-29
DE68929384T2 (de) 2002-11-21
NL300353I1 (nl) 2008-08-01
NL300350I1 (nl) 2008-08-01
ES2174859T3 (es) 2002-11-16
LU91448I2 (fr) 2008-07-29
ES2075019T3 (es) 1995-10-01

Similar Documents

Publication Publication Date Title
EP0359282B1 (fr) Anticorps monoclonaux spécifiques du récepteur du facteur de la croissance de l'épiderme humain et compositions thérapeutiques les contenant
US5720954A (en) Monoclonal antibodies directed to the HER2 receptor
Harwerth et al. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
US5587458A (en) Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0578774B1 (fr) Anticorps monoclonaux de recepteurs de facteurs de cellules souches
US6406870B2 (en) Methods and compositions for modulating heterotypic E-cadherin interactions with T lymphocytes
US5720937A (en) In vivo tumor detection assay
TWI338009B (en) Antibodies for inhibiting blood coagulation and methods of use thereof
US6024955A (en) Peptides and monoclonal antibodies
EP1641828B1 (fr) Anticorps anti-hgf-r et leur utilisation
CZ291047B6 (cs) Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk
WO2000034337A1 (fr) Anticorps monoclonaux humanises luttant contre un facteur de croissance de cellules endotheliales vasculaires
EP0805871A1 (fr) Anticorps anti-cd30 prevenant le clivage proteolytique et la liberation de l'antigene cd30 membranaire
KR20130083438A (ko) 간암 요법을 위한 방법 및 조성물
EP1350799A2 (fr) Polypeptides d'immunoglobulines inhibiteurs se liant au récepteur-beta humain de PDGF
US20020150574A1 (en) Antibodies against SEMP1 (p23)
KR101266389B1 (ko) 항 인간 테나신 단클론 항체
US20080317750A1 (en) Antibody antagonists of ve-cadherin without adverse effects on vascular permeability
KR20060003860A (ko) 내피 세포 특이적 항체 및 그의 용도
JP2002529516A (ja) ＣＤ６６ａを用いて新脈管形成に影響を及ぼす方法
JPH1087509A (ja) 腫瘍転移抑制剤
AU672377C (en) Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
JPH1149701A (ja) 抗癌剤
JPH09301888A (ja) 制癌剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19901009

17Q First examination report despatched

Effective date: 19921103

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19950524

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19950524

REF Corresponds to:

Ref document number: 123070

Country of ref document: AT

Date of ref document: 19950615

Kind code of ref document: T

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KRIS, RICHARD

Inventor name: SCHLESSINGER, JOSEPH

Inventor name: GIVOL, DAVID

Inventor name: BELLOT, FRANCOISE

XX Miscellaneous (additional remarks)

Free format text: TEILANMELDUNG 94117268.6 EINGEREICHT AM 15/09/89.

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

REF Corresponds to:

Ref document number: 68922808

Country of ref document: DE

Date of ref document: 19950629

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19950824

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2075019

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Free format text: RORER INTERNATIONAL (OVERSEAS) INC. TRANSFER- RORER INTERNATIONAL (HOLDINGS), INC. * RORER INTERNATIONAL (HOLDINGS), INC. TRANSFER- RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC.

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC.;

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC.

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

Ref country code: FR

Ref legal event code: CA

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: RHOENE-POULENC RORER INTERNATIONAL (HOLDINGS) INC

Free format text: RHOENE-POULENC RORER INTERNATIONAL (HOLDINGS) INC#3711 KENNETT PIKE SUITE 200#GREENVILLE (DE) (US) -TRANSFER TO- RHOENE-POULENC RORER INTERNATIONAL (HOLDINGS) INC#3711 KENNETT PIKE SUITE 200#GREENVILLE (DE) (US)

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUEA

Owner name: AVENTIS HOLDINGS INC.

Free format text: AVENTIS HOLDINGS INC.#3711 KENNETT PIKE, SUITE 200#GREENVILLE, DE 19807 (US) -TRANSFER TO- AVENTIS HOLDINGS INC.#3711 KENNETT PIKE, SUITE 200#GREENVILLE, DE 19807 (US) $ YEDA RESEARCH AND DEVELOPMENT CO. LTD.#THE WEIZMANN INSTITUTE OF SCIENCE P.O. BOX 95#76100 REHOVOT (IL)

Ref country code: CH

Ref legal event code: PUE

Owner name: AVENTIS HOLDINGS INC.

Free format text: RHOENE-POULENC RORER INTERNATIONAL (HOLDINGS) INC#3711 KENNETT PIKE SUITE 200#GREENVILLE (DE) (US) -TRANSFER TO- AVENTIS HOLDINGS INC.#3711 KENNETT PIKE, SUITE 200#GREENVILLE, DE 19807 (US)

REG Reference to a national code

Ref country code: FR

Ref legal event code: TQ

Ref country code: FR

Ref legal event code: TP

NLS Nl: assignments of ep-patents

Owner name: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Effective date: 20080606

Owner name: RHONE-POULENC RORER INC.

Effective date: 20080606

Owner name: AVENTIS HOLDINGS INC.

Effective date: 20080606

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20080926

Year of fee payment: 20

Ref country code: CH

Payment date: 20080930

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20080820

Year of fee payment: 20

Ref country code: NL

Payment date: 20080924

Year of fee payment: 20

Ref country code: FR

Payment date: 20080917

Year of fee payment: 20

NLS Nl: assignments of ep-patents

Owner name: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Effective date: 20080606

Owner name: AVENTIS HOLDINGS INC.

Effective date: 20080606

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20080929

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20081031

Year of fee payment: 20

Ref country code: LU

Payment date: 20081006

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20080929

Year of fee payment: 20

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20090914

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20090915

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090916

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20090915

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20090914

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20090916